SGEN

Seagen Inc. [SGEN] Stock Forecast

Buy or Sell ? Support and Resistance

What is MACD and how to read it?

How RSI can help?
RSI : 000

SGEN Stock Summary

Top 10 Correlated ETFs

SGEN


Top 10 Correlated Stocks

SGEN


In the News

02:32 29 Sep 2023 SGEN

Signal Says Buy Calls on This Biotech Stock

Biotech stock Seagen Inc (NASDAQ:SGEN) scored an all-time high of $215.04 today, building on a Friday breakout from a consolidation between $204 and $210.

12:01 29 Sep 2023 SGEN

Seagen's (SGEN) Combo Drug Meets Goals in Bladder Cancer Study

Seagen (SGEN) announces positive top-line results from its late-stage study of the Padcev/Keytruda combo in the treatment of adult patients with metastatic bladder cancer. The stock of the company rises 3.5%.

12:40 29 Sep 2023 SGEN

Seagen-Merck Bladder Cancer Treatment Shows Positive Results; Seagen Shares Jump

Biotechnology company Seagen Inc. (SGEN) and Tokyo-based Astellas Pharma Inc. on Friday reported positive results from a Phase 3 trial of their experimental bladder cancer medicine, Padcev, in combination with Merck's (MRK) Keytruda.

07:04 29 Sep 2023 SGEN

Flee to Healthcare Stocks if Recession Rears its Head?

If you're looking for a sector that's on sale, look to healthcare. The Health Care Select Sector SPDR Fund NYSEARCA: XLV is down 2.50% in the past month, lagging the S&P 500.

02:15 29 Sep 2023 SGEN

EU antitrust regulators set Oct. 19 deadline for Pfizer's Seagen deal

Pfizer's $43 billion bid for Seagen will be decided by EU antitrust regulators by Oct. 19, a regulatory filing showed on Friday.

08:12 29 Sep 2023 SGEN

Zai Lab ADR surges after Seagen, Genmab release cervical cancer treatment results

Zai Lab Ltd.'s American depositary receipts ZLAB, +2.47% jumped 14% premarket on Tuesday after Seagen Inc. SGEN, +0.89% and Genmab A/S GMAB, +0.24% announced that Tivdak, their treatment for cervical cancer, improved patients' overall survival in a late-stage study.

05:33 29 Sep 2023 SGEN

Genmab, Seagen say Tivdak cervical cancer trial met overall survival endpoint

Genmab A/S , and Seagen Inc on Monday said that the Phase III trial of Tivdak in recurrent or metastatic cervical cancer patients on or after front-line therapy met its primary endpoint of overall survival.

11:46 29 Sep 2023 SGEN

Seagen's (SGEN) Breast Cancer Study on Tuksya Combo Meets Goal

Seagen (SGEN) announces positive top-line results from its breast cancer study evaluating Tuksya in combination with Roche's Kadcyla.

08:34 29 Sep 2023 SGEN

Seagen's breast cancer therapy meets main goal in late-stage study

Seagen said on Wednesday its breast cancer therapy in combination with Roche's Kadcyla helped extend the time patients lived without their disease progressing in a late-stage trial.

01:48 29 Sep 2023 SGEN

3 Pharmaceutical Stocks to Buy and Hold for the Long Haul

There's a reason why many investors own one or more pharmaceutical stocks. This is a $1.2 trillion industry that is essential to the quality of life for many people.

SGEN Financial details

Company Rating
Buy
Market Cap
40.11B
Income
-725.25M
Revenue
2.16B
Book val./share
13.96
Cash/share
6.89
Dividend
-
Dividend %
-
Employees
3.26K
Optionable
No
Shortable
Yes
Earnings
25 Oct 2023
P/E
-54.89
Forward P/E
-
PEG
-106.89
P/S
18.43
P/B
15.2
P/C
30.8
P/FCF
-55.09
Quick Ratio
2.46
Current Ratio
1.69
Debt / Equity
0.04
LT Debt / Equity
0.04
-
-
EPS (TTM)
-3.89
EPS next Y
-
EPS next Q
-0.54
EPS this Y
-10.81%
EPS next Y
-
EPS next 5Y
-4.37%
EPS last 5Y
18.54%
Revenue last 5Y
24.55%
Revenue Q/Q
16.18%
EPS Q/Q
21.51%
-
-
-
-
SMA20
5.1%
SMA50
7.74%
SMA100
5.71%
Inst Own
95.22%
Inst Trans
1.07%
ROA
-21%
ROE
-26%
ROC
-0.28%
Gross Margin
76%
Oper. Margin
-35%
Profit Margin
-34%
Payout
-
Shs Outstand
187.7M
Shs Float
132.06M
-
-
-
-
Target Price
171.82
52W Range
116.08-214.0
52W High
-0.82%
52W Low
+82.97%
RSI
62.72
Rel Volume
1.11
Avg Volume
1.17M
Volume
1.3M
Perf Week
1.89%
Perf Month
9.77%
Perf Quarter
3.25%
Perf Half Y
4.54%
-
-
-
-
Beta
0.477178
-
-
Volatility
3.58%, 6.35%
Prev Close
-0.15%
Price
212.24
Change
-1.28%

SGEN Financial Performance

Yearly Fundamentals Overview

Last date of statement is 2022-12-31

Metric History 2018-12-312019-12-312020-12-312021-12-31 2022-12-31
Revenue per share
4.155.5412.448.6510.63
Net income per share
-1.41-0.383.51-3.7-3.3
Operating cash flow per share
-1.29-0.994.9-2.74-2.46
Free cash flow per share
-1.43-1.424.43-3.03-2.88
Cash per share
2.64.914.6411.879.4
Book value per share
8.0811.3419.9516.8415.18
Tangible book value per share
4.447.8616.7613.912.41
Share holders equity per share
8.0811.3419.9516.8415.18
Interest debt per share
-0.210.470.430.31-0.32
Market cap
8.93B18.91B30.62B28.14B23.73B
Enterprise value
8.85B18.71B30.14B27.78B23.46B
P/E ratio
-40.11-299.0149.9-41.73-38.89
Price to sales ratio
13.6420.6314.0717.8812.09
POCF ratio
-43.89-115.4935.75-56.4-52.3
PFCF ratio
-39.74-80.6439.55-51.05-44.69
P/B Ratio
7.0110.088.789.188.46
PTB ratio
7.0110.088.789.188.46
EV to sales
13.5220.4113.8517.6411.95
Enterprise value over EBITDA
-32.36-66.2552.14-40.35-37.61
EV to operating cash flow
-43.5-114.2835.18-55.66-51.69
EV to free cash flow
-39.4-79.838.93-50.38-44.17
Earnings yield
-0.0200.02-0.02-0.03
Free cash flow yield
-0.03-0.010.03-0.02-0.02
Debt to equity
-0.030.040.020.020.02
Debt to assets
-0.020.030.020.020.01
Net debt to EBITDA
0.290.7-0.840.530.44
Current ratio
2.43.356.853.82.12
Interest coverage
00005.92
Income quality
0.911.031.40.740.74
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.860.780.380.780.69
Intangibles to total assets
0.380.260.140.140.14
Capex to operating cash flow
0.10.43-0.10.10.17
Capex to revenue
-0.03-0.08-0.04-0.03-0.04
Capex to depreciation
-0.82-2.11-1.3-0.67-0.94
Stock based compensation to revenue
0.120.140.070.110.11
Graham number
16.039.8739.6937.4633.6
ROIC
-0.19-0.040.16-0.21-0.21
Return on tangible assets
-0.24-0.040.18-0.21-0.19
Graham Net
2.014.2413.4310.427.88
Working capital
268.39M608.98M2.27B1.59B916.67M
Tangible asset value
699.23M1.3B2.93B2.53B2.29B
Net current asset value
230.48M538.76M2.15B1.51B864.36M
Invested capital
-0.030.040.020.020.02
Average receivables
115.53M191.14M280.49M357.12M445.58M
Average payables
36.77M48.24M65.18M96.45M161.34M
Average inventory
56.61M69.59M101.03M158.4M313.94M
Days sales outstanding
81.5593.9754.5290.2493.35
Days payables outstanding
182.63434.26130.88134.52185.01
Days of inventory on hand
220.09713.62194.7235.08380.27
Receivables turnover
4.483.886.694.043.91
Payables turnover
20.842.792.711.97
Inventory turnover
1.660.511.871.550.96
ROE
-0.17-0.030.18-0.22-0.22
Capex per share
-0.13-0.43-0.47-0.29-0.42

Quarterly Fundamentals Overview

Last date of statement is 2023-06-30 for Q2

Metric History 2022-06-302022-09-302022-12-312023-03-31 2023-06-30
Revenue per share
2.72.762.842.783.22
Net income per share
-0.73-1.03-0.8-0.93-1.13
Operating cash flow per share
-0.39-0.46-0.43-1.34-0.93
Free cash flow per share
-0.47-0.55-0.58-1.54-1.2
Cash per share
10.059.549.327.976.89
Book value per share
15.9315.2715.0714.5713.96
Tangible book value per share
13.0812.4712.3111.8611.29
Share holders equity per share
15.9315.2715.0714.5713.96
Interest debt per share
0.290.210.010.220.52
Market cap
32.58B25.29B23.91B37.84B36.1B
Enterprise value
32.27B24.97B23.64B37.59B35.89B
P/E ratio
-60.42-33.13-40.35-54.14-42.66
Price to sales ratio
65.4949.5545.2872.8159.78
POCF ratio
-453.99-294.94-301.04-151.57-205.98
PFCF ratio
-376.53-248.71-220.04-131.25-160.81
P/B Ratio
11.118.968.5313.913.78
PTB ratio
11.118.968.5313.913.78
EV to sales
64.8648.9344.7672.3459.43
Enterprise value over EBITDA
-290.45-141.72-143.98-189-154.15
EV to operating cash flow
-449.6-291.26-297.56-150.59-204.78
EV to free cash flow
-372.89-245.61-217.49-130.4-159.87
Earnings yield
0-0.01-0.010-0.01
Free cash flow yield
000-0.01-0.01
Debt to equity
0.020.020.020.030.04
Debt to assets
0.010.010.010.030.03
Net debt to EBITDA
2.831.791.681.230.91
Current ratio
4.573.82.122.091.69
Interest coverage
-41.3622.533.743.630
Income quality
0.530.450.541.430.83
Dividend Yield
00000
Payout ratio
00000
Sales general and administrative to revenue
00000
Research and developement to revenue
0.610.750.680.690.66
Intangibles to total assets
0.140.140.140.140.14
Capex to operating cash flow
0.210.190.370.150.28
Capex to revenue
-0.03-0.03-0.06-0.07-0.08
Capex to depreciation
-0.72-0.76-1.41-1.75-2.28
Stock based compensation to revenue
0.110.120.120.120.15
Graham number
16.218.8416.4317.5118.82
ROIC
-0.04-0.07-0.05-0.07-0.08
Return on tangible assets
-0.04-0.06-0.05-0.06-0.07
Graham Net
8.918.197.826.855.86
Working capital
2.17B2.03B916.67M777.04M529.22M
Tangible asset value
2.41B2.3B2.29B2.22B2.12B
Net current asset value
2.08B1.96B864.36M670.13M415.8M
Invested capital
0.020.020.020.030.04
Average receivables
419.53M462.4M494.33M498.84M540.91M
Average payables
108.05M136.69M176.18M174.66M127.95M
Average inventory
297.55M342.16M396.09M452.45M482.27M
Days sales outstanding
79.2485.8585.5385.8587.35
Days payables outstanding
109.32120.28172.87113.9156.97
Days of inventory on hand
270.89303.8355.32384.63242.41
Receivables turnover
1.141.051.051.051.03
Payables turnover
0.820.750.520.791.58
Inventory turnover
0.330.30.250.230.37
ROE
-0.05-0.07-0.05-0.06-0.08
Capex per share
-0.08-0.09-0.16-0.21-0.26

SGEN Frequently Asked Questions

What is Seagen Inc. stock symbol ?

Seagen Inc. is a US stock , located in Bothell of Wa and trading under the symbol SGEN

Is Seagen Inc. buy or a sell ?

13 stock analysts have 13 predictions with a medium analyst target price of $166. The lowest prediction is $120 and the highest is $222

What is SGEN stock prediction ?

What is Seagen Inc. stock quote today ?

Seagen Inc. stock price is $212.24 today.

Is Seagen Inc. stock public?

Yes, Seagen Inc. is a publicly traded company.

Something similar

Top by Market Cap
Top Correlated ETFs
Top Correlated Stocks
Similar Market Cap